FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.
AstraZeneca, a global, science-led biopharmaceutical company, announced that its Imfinzi (durvalumab) has been recommended for approval in the European Union (EU) as monotherapy for the treatment of ...
AstraZeneca’s (AZN) Imfinzi has been recommended for approval in the European Union, EU, as monotherapy for the treatment of adults with limited-stage small cell lung cancer, LS-SCLC ...
AstraZeneca’s (AZ) Imfinzi (durvalumab) has been recommended by the European Medicines Agency’s human medicines committee to treat an aggressive form of lung cancer. The Committee for Medicinal ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback